Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonology.
Because of their small size, unique structure and extreme stability, Nanobodies combine the advantages of conventional antibody drugs with the features of small-molecule drugs.
The Company has approximately 30 programmes in the pipeline and seven Nanobodies are in clinical development. Potent functional Nanobodies have been generated to therapeutically relevant targets of all major classes, including cytokines, enzymes, cell surface receptors such as receptor tyrosine kinases and GPCRs, as well as ion channels.
Ablynx has on-going research collaborations and important partnerships with key pharmaceutical players, including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck Serono, Merck & Co and Novartis.
Ablynx has a strong and broad patent portfolio of 550 patent applications and granted patents covering various aspects of the discovery, generation, optimalisation, formatting, manufacture, administration, formulation and clinical use of Nanobodies, as well as covering its clinical development programmes and product candidates. This, combined with the extensive experience and expertise that Ablynx has established as the first company to discover and develop Nanobodies and to achieve clinical proof-of-concept for multiple clinical programmes, puts Ablynx in a unique position to exploit the Nanobody platform in the field of therapy and diagnosis.
Ablynx is also the holder worldwide of the trademarks Ablynx®, Nanobody® and Nanoclone®.